🇺🇸 FDA
Patent

US 10117915

Modulation of yeast-based immunotherapy products and responses

granted A61KA61K2039/505A61K2039/523

Quick answer

US patent 10117915 (Modulation of yeast-based immunotherapy products and responses) held by The Regents of the University of Colorado, a Body Corporate expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/523, A61K2039/57, A61K36/06